Core Insights - Klotho Neurosciences, Inc. will participate in the Longevity Biotech 2025 conference in Boston on October 22-23, 2025, focusing on advancing longevity therapeutics [1][2] - The company aims to engage in one-on-one meetings with investors and potential partners during the event to discuss collaborations and therapeutic programs [2] - Klotho specializes in developing innovative cell and gene therapies targeting neurodegenerative and age-related disorders, leveraging a patented form of the "anti-aging" human Klotho gene [3] Company Overview - Klotho Neurosciences, Inc. is a biogenetics company listed on NASDAQ (KLTO) [3] - The company focuses on disease-modifying therapies for conditions such as ALS, Alzheimer's disease, and Parkinson's disease [3] - Klotho's portfolio includes proprietary cell and gene therapy programs utilizing DNA and RNA therapeutics, along with genomics-based diagnostic assays [3]
Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston